MEDIAN Technologies Obtains "Innovative Company" Accreditation From OSEO (the French State Innovation Agency) and is Now Eligible for Tax-Efficient Investments by FCPI Closed-End Funds

By Median Technologies, PRNE
Sunday, November 28, 2010

The Company Provides Innovative FDA-Cleared and CE-Marked Lesion Management Solutions (LMSs) for Cancer Diagnosis and Follow-up.

SOPHIA ANTIPOLIS, NICE, France, November 29, 2010 - MEDIAN Technologies, the leading provider of clinical applications for
quantitative management of treatment responses in oncology imaging, today
announced that it had obtained "Innovative Company" accreditation from OSEO
(the French state innovation agency). This accreditation enables
innovation-focused French investment funds (Fonds Communs de Placement dans
l'Innovation) to invest in MEDIAN Technologies and enjoy a number of fiscal

MEDIAN Technologies has ISO 13485 certification - the internationally
recognized quality standard for the medical device industry. The company's
LMSs gained FDA approval in 2007 and a class IIa CE mark was awarded in 2010.
The LMSs are used by key opinion leaders in over 102 centres in Europe, the
USA and (most recently) Australia.

"Receiving OSEO Innovative Company accreditation emphasizes MEDIAN
Technologies' focus on innovation and proves the relevance of our software
solutions and services. In fact, our solutions provide the pharmaceutical
industry and physicians with essential tools based on new-generation
biomarkers, which help detect cancerous lesions early and optimise patient
follow-up", commented MEDIAN Technologies' Chairman and CEO Fredrik Brag.

Whilst medical imaging is an important tool, standard methods for image
interpretation do not enable all lesions to be detected and optimally
monitored over time. MEDIAN Technologies offers the pharmaceutical industry
and the medical world a number of integrated LMSs which help interpret
medical images and thus improve the diagnosis and monitoring of cancer
patients. The LMS software automatically quantifies the lesions and allows
the flexible, effective management of lesion-related information. In
combination with high levels of automation and standardization, the LMS uses
biomarker identification to assist with lesion detection, interpretation,
quantification and monitoring over time.

MEDIAN Technologies is targeting the oncology clinical trial market, its
primary market, and the cancer patient care market.

For more information about MEDIAN Technologies, visit:

    Press contacts

    MEDIAN Technologies
    Fredrik Brag, CEO

    Caroline Carmagnol
    +33-6-64-18-99-59 // +33-1-42-68-86-43

Press contacts: MEDIAN Technologies, Fredrik Brag, CEO, +33-492-90-65-82, fredrik.brag at . ALIZE RP, Caroline Carmagnol, +33-6-64-18-99-59 // +33-1-42-68-86-43, caroline at .

will not be displayed